 |
110 Diseases |  |
151 Trials |
|
151 Trials |  |
7120 News |  |
| «12...2627282930313233343536...8687» |
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Observational data, Clinical Trial,Phase III, Journal, Real-world evidence: Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea. (Pubmed Central) - Jul 13, 2022
The safety and effectiveness of denosumab in Korean patients with osteoporosis in this study were comparable with those in the Korean randomized controlled trial, with no new safety findings.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: A female patient with earache, polyuria and polydipsia (Pubmed Central) - Jul 13, 2022
Langerhans cell histiocytosis involving cranial bones is often associated with diabetes Insipidus. Knowledge about the distinctive constellation may lead to a more rapid diagnosis and improved prognosis.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Editorial: Calcium: An Overview From Physiology to Pathological Mineralization. (Pubmed Central) - Jul 13, 2022
Knowledge about the distinctive constellation may lead to a more rapid diagnosis and improved prognosis. No abstract available
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Malignant Transformation of Giant Cell Tumor of Bone and the Association with Denosumab Treatment: A Radiology and Pathology Perspective. (Pubmed Central) - Jul 12, 2022
Close clinical and imaging follow-up during the first months of denosumab therapy is key, as mGCTB tends to have rapid aggressive behavior, similar to other high-grade sarcomas. Nonresponders should be (re) evaluated for their primary diagnosis of conventional GCTB.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Retrospective data, Journal: Treatment of Giant Cell Tumor of Bone in the Distal Radius and Ulna (Pubmed Central) - Jul 12, 2022
In 6 patients denosumab treatment was indicated...En bloc tumor resection and reconstruction using an osteocartilaginous allograft is a suitable treatment option for a locally advanced tumor with a low risk of local recurrence. Key words: giant cell tumor of bone, distal radius, distal ulna, curettage, osteocartilaginous allograft.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial. (Pubmed Central) - Jul 10, 2022
The accumulate recurrence-free survival rate at 4-year follow-up is higher in DB group (p = 0.035). Denosumab is a safe but costly alternative to zoledronic acid for treatment of surgically unsalvageable GCTB.
- || Xofigo (radium Ra-223 dichloride) / Bayer
P1 data, P2a data, Journal: A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results. (Pubmed Central) - Jul 10, 2022
Capecitabine + Ra at the planned dose was safe and feasible in MBC patients with bone metastases. However, no efficacy signals were seen that might suggest greater efficacy of the combination over capecitabine alone clinically or biochemically.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Retrospective data, Journal: Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications. (Pubmed Central) - Jul 9, 2022
Increasing the interval of denosumab dosing for GCTB provided similar tumor control compared to standard dosing and lower absolute number of bone toxicity events. Larger studies are needed to better define the optimal interval of denosumab administration and the effect on efficacy, toxicity, and associated healthcare expense.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: The relationship between chronic kidney disease and denosumab-induced hypocalcemia in high-age osteoporotic patients. (Pubmed Central) - Jul 9, 2022
Larger studies are needed to better define the optimal interval of denosumab administration and the effect on efficacy, toxicity, and associated healthcare expense. Advanced age combined with low eGFR and low serum Ca status appear to be associated with the incidence of hypocalcemia when using denosumab for the treatment of osteoporosis.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Denosumab is much much more expensive than Zolendronic acid and the differenc ein benefit is not that spectacular 3 month diff in skeletal related events More hypocalcemia and osteonecrosis in Denosumab https://t.co/8dJw3FzYqg dont this OS data was published but could be wrong (Twitter) - Jul 9, 2022
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal, IO biomarker: Severe and refractory hypocalcaemia secondary to osteoblastic bone metastases in bladder signet ring carcinoma: A case report and literature review. (Pubmed Central) - Jul 9, 2022
It is rare and has not been described in bladder cancer. Precaution should be taken upon the initiation of antiresorptive in patients with osteoblastic bone metastases.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Zentrales Riesenzellgranulom in der Mandibula. Therapie bei einem 13-jährigen Patienten mit Denosumab. (Pubmed Central) - Jul 7, 2022
Precaution should be taken upon the initiation of antiresorptive in patients with osteoblastic bone metastases. No abstract available
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal, Real-world evidence: Real-world data on vitamin D supplementation and its impacts in systemic lupus erythematosus: Cross-sectional analysis of a lupus registry of nationwide institutions (LUNA). (Pubmed Central) - Jul 7, 2022
Even with a possible Vitamin D deficiency and a high risk of bone fractures in SLE patients, only half of our cohort received its supplementation. The effect of vitamin D supplementation for disease activity control was not observed.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal, Real-world evidence: The real-world effectiveness of anti-RANKL antibody denosumab on the clinical fracture prevention in patients with rheumatoid arthritis: The ANSWER cohort study. (Pubmed Central) - Jul 6, 2022
The effect of vitamin D supplementation for disease activity control was not observed. Denosumab suppresses the risk of clinical fractures in patients with RA.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study. (Pubmed Central) - Jul 6, 2022
The crude fracture rate in bisphosphonate users was 72.1/1000 person-year, in denosumab users was 58.2/1000 person-year, and in teriparatide users was 19.3/1000 person-year...The effect of bisphosphonate on fracture risk was apparent only after the first year of treatment. Our findings do not support the use of bisphosphonates in patients at imminent risk of fracture.
- || LY01011 (denosumab biosimilar) / Luye Group
Clinical, Journal: A Randomized Controlled Dose-Escalation Study of LY06006, a Recombinant Humanized Monoclonal Antibody to RANKL, in Chinese Healthy Adults. (Pubmed Central) - Jul 6, 2022
Single-dose subcutaneous administration of LY06006 was safe and well-tolerated in healthy Chinese adults. C showed linear pharmacokinetic characteristics in the dose range of 18-120 mg based on dose-exposure proportionality analysis.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Adjuvant Denosumab therapy following curettage and external fixator for a giant cell tumor of the distal radius presenting with a pathological fracture: A case report. (Pubmed Central) - Jul 6, 2022
External fixation and adjuvant denosumab may be considered as an option in patients who are not suitable for internal fixation. However, cohort studies with long term follow up is necessary before it can be recommended in routine practice.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Effect of different schemes of androgen deprivation therapy on bone mass density in prostate cancer patients. (Pubmed Central) - Jul 5, 2022
Bone health assessment and fracture risk evaluation are convenient in these patients. In a real-world setting, the effect of denosumab in BMD is detected, however the effect of intermittent LH-RH schema treatment is less evident.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Immobilisation hypercalcaemia. (Pubmed Central) - Jul 5, 2022
Management of immobilisation hypercalcaemia revolves around early mobilisation and rehabilitation together with pharmacotherapeutic agents such as intravenous isotonic saline, calcitonin and bisphosphonates. Denosumab may be a potential alternative yet off-label treatment for immobility hypercalcaemia in patients with renal insufficiency.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Risk Factors for Denosumab Discontinuation in Patients with Postmenopausal Osteoporosis. (Pubmed Central) - Jul 5, 2022
Denosumab may be a potential alternative yet off-label treatment for immobility hypercalcaemia in patients with renal insufficiency. A low BMI, low serum Alb levels, and a high number of VFs were associated with denosumab discontinuation in patients with PMO.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo, Keytruda (pembrolizumab) / Merck (MSD)
Clinical: How do you interpret "worsening SUV in bony mets on PET scan, but no change in size"? The patient (stage 4 basal cell with extensive bone only mets) is asymptomatic on Keytruda and xgeva. (Twitter) - Jul 5, 2022
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
@Amgen that Prolia commercial w the liquid on the floor was terrifying 🤣 thanks for the awareness 👍 (Twitter) - Jul 4, 2022
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Management of medication-related osteonecrosis of the jaw-a review of recent study results in comparison to established strategies (Pubmed Central) - Jul 2, 2022
MRONJ treatment should be initiated early and involve a surgical approach. MRONJ treatment is safe and predictable, with long-term success rates of more than 85%.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical data, Review, Journal: Surgical challenges, novel techniques, and systemic treatment of giant cell tumour of bone of the distal radius : clinical outcomes and systematic review of the literature. (Pubmed Central) - Jul 2, 2022
The large majority of patients however, were cured after repeated curettage. Cite this article: Bone Jt Open 2022;3(7):515-528.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Biomarker, Journal: Dipeptidyl Peptidase 3 Activity as a Promising Biomarker of Bone Fragility in Postmenopausal Women. (Pubmed Central) - Jul 1, 2022
We aimed to assess the association of Dpp3 activity with bone fragility in postmenopausal osteoporosis and the impact of denosumab on enzymatic activity...Our findings support a critical role played by Dpp3 in bone homeostasis as a potential bone protective factor. Additional clinical studies in larger cohorts might explore the implementation of Dpp3 assessment as a biomarker of bone health status.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
I have seen post- Denosumab secondary hyper-parathyroidism last for 9 months, following a single injection.. (Twitter) - Jul 1, 2022
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, Avastin (bevacizumab) / Roche, Sutent (sunitinib) / Pfizer
Review, Journal: Emerging antiresorptive medications and their potential implications for dental surgeries. (Pubmed Central) - Jun 30, 2022
Antiangiogenic agents, bevacizumab, aflibercept, and tyrosine kinase inhibitors such as sunitinib were implicated most commonly in the development of MRONJ. Patients who are taking multiple doses of angiogenic inhibitors should be monitored closely for early diagnosis of possible MRONJ.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Bilateral Atypical Femur Fractures After Denosumab in a Bisphosphonate Naive Patient: A Case Report. (Pubmed Central) - Jun 29, 2022
AFFs may be associated with patients on denosumab therapy even without a prior history of bisphosphonate use. Patients should be counselled appropriately and monitored for such complications.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Raloxifene Use After Denosumab Discontinuation Partially Attenuates Bone Loss in the Lumbar Spine in Postmenopausal Osteoporosis. (Pubmed Central) - Jun 29, 2022
Compared to BMD at DMab initiation, DR partially retained BMD gain by DMab treatment in lumbar spine (+ 3.7%, p = 0.003) and femoral neck (+ 2.8%, p = 0.010), whereas DD did not. Raloxifene use after DMab treatment attenuated lumbar spine BMD loss in postmenopausal women with short exposures (< 2 years) to DMab.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal, Real-world evidence: Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in Greece. (Pubmed Central) - Jun 29, 2022
Less than half of the estimated number of individuals with osteoporosis in 2019 in Greece received treatment, with the total annual cost being far less than the estimated cost of incident-fragility fractures. The impact of this undertreatment on related health care costs merits further investigation.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial. (Pubmed Central) - Jun 28, 2022
P2
The impact of this undertreatment on related health care costs merits further investigation. Although no differences in erosion parameters were observed at 12 months, denosumab was more efficacious than placebo in erosion repair on HR-pQCT after 24 months.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Interstitial Lung Disease in a Woman with Rheumatoid Arthritis Treated with Denosumab: A Case Report. (Pubmed Central) - Jun 28, 2022
The patient's respiratory discomfort and the finding of interstitial lung lesion in CT imaging improved after Dmab discontinuation. This case showed that exacerbation of ILD may occur after Dmab treatment, and physicians should consider the risks of Dmab-related ILD in patients with RA complicated by ILD.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club. (Pubmed Central) - Jun 28, 2022
Although the pathophysiology of solid organ and hematopoietic stem cell transplantation-induced osteoporosis extends beyond GIOP alone, the BBC recommends similar evaluation, prevention, treatment and follow-up principles in these patients. Efforts to close the treatment gap in GIOP and implement available effective fracture prevention strategies into clinical practice in primary, secondary and tertiary care are urgently needed.
- | Prolia (denosumab) / Amgen
New trial, Metastases: PRaG2X: PraG With RANKL Inhibitor for the Treatment of Advanced Multiple Metastatic Solid Tumors (clinicaltrials.gov) - Jun 27, 2022
P=N/A, N=51, Not yet recruiting, Sponsor: Second Affiliated Hospital of Soochow University
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Unresectable Clival Giant Cell Tumor, Tumor Control With Denosumab After Relapse: A Case Report and Systematic Review of the Literature. (Pubmed Central) - Jun 25, 2022
However, the definitive treatment is still controversial because of their rarity and few follow-up data. The present case highlights the benefit of denosumab and its safety as long-term therapy and contributes to the existing literature with analysis and evaluation of the management strategies and prognosis.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
P2 data, Journal: Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study. (Pubmed Central) - Jun 25, 2022
Denosumab induces ALP/OCN and s-CTX reduction. High baseline s-CTX identifies a group of patients at higher risk of progression of the disease.
- |||||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Review: Nice comparison of ABCSG-18 vs D-CARE on adjuvant denosumab use in early breast cancer: different pt population, different doses of medication, different outcomes. Wonderful review on adjuvant studies in breast cancer by Dr. @hmcarthur @ASCO @UTHealthSAMDA (Twitter) - Jun 25, 2022
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Sclerostin Immunohistochemical Staining in Aggressive Maxillofacial Giant Cell Lesions: Initial Results and Potential Therapeutic Target. (Pubmed Central) - Jun 24, 2022
High baseline s-CTX identifies a group of patients at higher risk of progression of the disease. Maxillofacial GCLs have an overall high level of SOST staining; however, the role of SOST in treatment and prognosis is unknown and warrants further study.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Clinical protocol, Journal: Effect of a single-dose denosumab on semen quality in infertile men (the FITMI study): study protocol for a randomized controlled trial. (Pubmed Central) - Jun 24, 2022
P2
We describe a protocol for a planned RCT aimed at evaluating whether treatment with denosumab can improve the semen quality in infertile men selected by using serum AMH as a positive predictive biomarker. The results will provide evidence crucial for future treatment in a patient group where there is a huge unmet need.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Experience with Denosumab in central giant-cell granuloma (Pubmed Central) - Jun 24, 2022
The results will provide evidence crucial for future treatment in a patient group where there is a huge unmet need. the use of Denosumab as the first line of treatment in Giant Cell Granu loma may be an adequate therapeutic option in adolescents with lesions that are difficult to resect.
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
My concern about widespread uptake of denosumab, esp in women who have osteopenia/porosis, is many docs don’t know you can’t just stop it after X years. Rebound bone loss and increased risk of vertebral fractures will require use of bisphosphonates. Not sure all understand that (Twitter) - Jun 24, 2022
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Review, Journal: Risk of developing spontaneous MRONJ in fibrous dysplasia patients treated with bisphosphonates: a systematic review of the literature. (Pubmed Central) - Jun 23, 2022
the use of Denosumab as the first line of treatment in Giant Cell Granu loma may be an adequate therapeutic option in adolescents with lesions that are difficult to resect. Patients with fibrous dysplasia or fibrous dysplasia/McCune-Albright syndrome have a low incidence of MRONJ and may apparently have low susceptibility to spontaneous development of MRONJ.
- |||| Prolia (denosumab) / Amgen, Daiichi Sankyo, zoledronic acid / Generic mfg.
Clinical: ABCSG-12 showed the same yrs ago w/ zoledronic acid too. D-CARE with denosumab did not. Fx prevention was primary endpoint of all these trials. My takeaway is not 💯 certain, but it certainly prevents fracture and doesn't hurt. Will try for patients, sometimes coverage is??? (Twitter) - Jun 23, 2022
- | Prolia (denosumab) / Amgen, Daiichi Sankyo, Evenity (romosozumab) / Astellas, Amgen, UCB
Journal: Secular Trends in the Pharmacologic Treatment of Osteoporosis and Malignancy-Related Bone Disease from 2009 to 2020. (Pubmed Central) - Jun 22, 2022
Rates of denosumab use outpaced growth of all other bone-directed therapies over the past decade. Treatment rates after osteoporotic fractures were low and declined over time, highlighting major failings in osteoporosis treatment in the US.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, Asclera (polidocanol) / Merz Pharma
Review, Journal: Minimally invasive treatment of aneurysmal bone cysts: systematic literature review. (Pubmed Central) - Jun 22, 2022
Radiation therapy is not a first-line treatment because of its side effects. Bisphosphonates and denosumab can be used when the other treatments are contraindicated.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Spine volumetric BMD and strength in premenopausal idiopathic osteoporosis: Effects of teriparatide followed by denosumab. (Pubmed Central) - Jun 22, 2022
Bisphosphonates and denosumab can be used when the other treatments are contraindicated. The large and statistically significant increases in volumetric density and stiffness after sequential treatment with teriparatide followed by denosumab are encouraging and support use of this regimen in PreMenIOP.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Simplified Choice of Suitable Excipients within Biologics Formulation Design using Protein-Protein Interaction- and Water Activity-Maps. (Pubmed Central) - Jun 22, 2022
The approach is extends by studying the long-term stability of the predicted formulation conditions for a γ globulin from human blood and denosumab. The results reveal, that by combining protein-specific experiments as well as model-based studies for the selection of excipient mixtures in high concentration protein formulations, the effort as well as the resource requirements can be reduced significantly.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal, HEOR: Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea. (Pubmed Central) - Jun 22, 2022
The results reveal, that by combining protein-specific experiments as well as model-based studies for the selection of excipient mixtures in high concentration protein formulations, the effort as well as the resource requirements can be reduced significantly. The findings of this analysis suggest that denosumab is a cost-effective therapeutic option for preventing fractures in postmenopausal women with osteoporosis in South Korea.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Effect of Denosumab on the Change of Osteoclast Precursors Compared to Zoledronate Treatment in Postmenopausal Women with Osteoporosis. (Pubmed Central) - Jun 22, 2022
During denosumab treatment, old age and suppressed bone turnover were associated with increased OC precursor cell populations. Further validation studies with prospective designs are required.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Retrospective data, Journal: Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies. (Pubmed Central) - Jun 22, 2022
However, denosumab had a lower incidence of composite cardiovascular disease, and may be a better option for the population with cardiovascular disease. Nonetheless, due to limitations like a short-term follow-up, gender, and incomplete types of adverse effects, more randomized controlled trials (RCTs) are required to further verify this conclusion.